Structure−Activity Relationships in Platelet-Activating Factor. 12. Synthesis and Biological Evaluation of Platelet-Activating Factor Antagonists with Anti-HIV-1 Activity
Authors:
- Marc MartinMMMarc Martin
- Okkacha BensaidOBOkkacha Bensaid
- Salvatore CisterninoSalvatore Cisternino
- Christophe RousselleCRChristophe Rousselle
- Nathalie Dereuddre-BosquetNDNathalie Dereuddre-Bosquet
- Jack HuetJHJack Huet
- Catherine RedeuilhCRCatherine Redeuilh
- Aazdine LamouriALAazdine Lamouri
- Chang-Zhi DongCDChang-Zhi Dong
- Pascal ClayettePCPascal Clayette
- Jean-Michel ScherrmannJSJean-Michel Scherrmann
- 10 November 2004
- journal article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 47 (25) , 6410-6419
Abstract
The HIV-1 central nervous system infection leads to the onset of neurological impairments called AIDS dementia complex (ADC). PAF plays an important role in this pathology, as it is an HIV-1-induced neurotoxin produced by infected or activated macrophages and microglia, in the brain. We previously reported that PAF-antagonists bearing a trisubstituted piperazine presented in vitro anti-HIV-1 activity in human macrophages. To improve the pharmacological activities of our lead compound, 1a, we modified its carbamate function and evaluated both its antiretroviral and anti-PAF activities. One carbamate derivative (10c) demonstrated a similar antiviral activity but a higher anti-PAF potency, whereas 4a, with an ureide function, presents an increased antiviral activity and can be considered as a pure antiretroviral drug, as it does not present PAF-antagonism. Moreover, we measured the ability of 1a to cross the blood−brain barrier, using the in situ mouse brain perfusion method and its plasmatic concentrations after iv and po administration. The transport parameter measured (Kin) proves that 1a is able to cross this biological barrier, but a pharmacokinetic study reveals its weak bioavailability in rats.Keywords
This publication has 13 references indexed in Scilit:
- PMS-601, a New Platelet-Activating Factor Receptor Antagonist That Inhibits Human Immunodeficiency Virus Replication and Potentiates Zidovudine Activity in MacrophagesAntimicrobial Agents and Chemotherapy, 2000
- Structure−Activity Relationships in Platelet-Activating Factor (PAF). 10. From PAF Antagonism to Inhibition of HIV-1 ReplicationJournal of Medicinal Chemistry, 2000
- Reservoirs for HIV-1: Mechanisms for Viral Persistence in the Presence of Antiviral Immune Responses and Antiretroviral TherapyAnnual Review of Immunology, 2000
- Development of an In Situ Mouse Brain Perfusion Model and its Application to mdr1a P-Glycoprotein-Deficient MiceJournal of Cerebral Blood Flow & Metabolism, 2000
- Platelet-activating Factor Receptor ActivationJournal of Biological Chemistry, 1998
- Dementia Associated with the Acquired Immunodeficiency SyndromeNew England Journal of Medicine, 1995
- Temporal trends in the incidence of HTV‐1‐related neurologic diseasesNeurology, 1994
- Design and modeling of new platelet-activating factor antagonists. 1. Synthesis and biological activity of 1,4-bis(3',4',5'-trimethoxybenzoyl)-2-[[(substituted carbonyl and carbamoyl)oxy]methyl]piperazinesJournal of Medicinal Chemistry, 1993
- A platelet-activating factor antagonist, RP 55778, inhibits cytokine-dependent induction of human immunodeficiency virus expression in chronically infected promonocytic cells.Proceedings of the National Academy of Sciences, 1993
- Cytokines and arachidonic metabolites produced during human immunodeficiency virus (HIV)-infected macrophage-astroglia interactions: implications for the neuropathogenesis of HIV disease.Journal of Experimental Medicine, 1992